Synthetic Biologics Inc (NYSEMKT:SYN) Director Steve H Kanzer sold 263,112 shares of the stock on the open market in a transaction dated Thursday, May 1st. The shares were sold at an average price of $ 2.90, for a total value of $ 763,024.80. Synthetic Biologics Inc (NYSEMKT:SYN) shares after opening at $1.46 moved to $1.51 on last trade day and at the end of the day closed at $1.30 . Company price to cash ratio in past twelve months was calculated as 5.19. Synthetic Biologics Inc (NYSEMKT:SYN) showed a negative weekly performance of -54.23%.
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Director Torsten Rasmussen sold 32,857 shares of the stock on the open market in a transaction dated Thursday, May 1st. The shares were sold at an average price of $20.03, for a total value of $658,125.71. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares fell -2.63% in last trading session and ended the day on $19.59. ACAD return on equity ratio is recorded as -24.30% and its return on assets is -21.70%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) yearly performance is 58.88%.
Biogen Idec Inc (NASDAQ:BIIB) CEO George A. Scangos sold 2,123 shares of Biogen Idec stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $285.56, for a total value of $606,243.88. Following the completion of the sale, the chief executive officer now directly owns 24,019 shares in the company, valued at approximately $6,858,866. Biogen Idec Inc (NASDAQ:BIIB) shares moved down -1.65% in last trading session and was closed at $282.01 while trading in range of $280.01 – $290.61 – Biogen Idec Inc (NASDAQ:BIIB) year to date (YTD) performance is 0.87%.
Illumina Inc (NASDAQ:ILMN) Director Daniel Bradbury sold 2,100 shares of Illumina stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $139.66, for a total transaction of $293,286.00. Following the sale, the director now directly owns 9,924 shares in the company, valued at approximately $1,385,986. Illumina, Inc. (NASDAQ:ILMN) weekly performance is -0.39%. On last trading day company shares ended up $139.16. Illumina, Inc. (NASDAQ:ILMN) distance from 50-day simple moving average (SMA50) is -9.73%. Analysts mean target price for the company is $176.97.
Leave a Reply